CDAC CLL

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Dr. Constantine S. Tam presents preliminary results from the Phase 1 CaDAnCe-101 study, highlighting the promising efficacy and safety of the BTK degrader BGB-16673 in heavily pretreated patients with relapsed or refractory CLL/SLL, including those with BTK inhibitor resistance and Richter transformation.

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study